Plain-English translation of NCT06731478 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called (Enhertu) combined with and sometimes an immunotherapy drug called . Researchers want to see if this new combination works better and is safer than the current standard treatment for people with advanced stomach cancer that has a specific marker called HER2-positive. You would be randomly assigned to receive either the new medication combination or the current standard treatment.
Stomach cancer that has spread or cannot be surgically removed is very serious and hard to treat. This medication is designed to target HER2-positive cancer cells more directly while also working with the body's immune system, and early results suggest it may help people live longer and feel better than current options.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for treatment and monitoring over several months or longer. Depending on which group you are randomly assigned to, you would receive intravenous infusions (through a vein) of the new medication or standard , sometimes along with other medications by mouth or infusion. You would have blood tests and imaging scans periodically to see how well the treatment is working and to check for any side effects. The trial team would carefully track how you respond to treatment and how you feel throughout the study.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States